Mutational study of the "catalytic tetrad" of DNA topoisomerase IB from the hemoflagellate Leishmania donovani: Role of Asp-353 and Asn-221 in camptothecin resistance

Biochemical Pharmacology

Volumn 76, Issue 5, 2008, Pages 608-619

  Diaz González, Rosario ^a   Pérez Pertejo, Yolanda ^a   Pommier, Yves ^b   Balaña Fouce, Rafael ^a   Reguera, Rosa M ^a  

^a UNIVERSITY OF LEÓN   (Spain)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Camptothecin; Leishmania; Site directed mutagenesis; Topoisomerase IB; Tropical diseases; Trypanosomatids

Indexed keywords

CAMPTOTHECIN; DNA TOPOISOMERASE;

ARTICLE; DNA CLEAVAGE; DRUG RESISTANCE; DRUG SENSITIVITY; GENE EXPRESSION SYSTEM; LEISHMANIA DONOVANI; MOLECULAR CLONING; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PURIFICATION; SEQUENCE ALIGNMENT; SITE DIRECTED MUTAGENESIS;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; ASPARAGINE; ASPARTIC ACID; BASE SEQUENCE; BINDING SITES; CAMPTOTHECIN; CATALYSIS; DNA PRIMERS; DNA TOPOISOMERASES, TYPE I; DRUG RESISTANCE; ENZYME INHIBITORS; FLAGELLA; LEISHMANIA DONOVANI; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; PROTOZOAN PROTEINS;

EID: 49149110065     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.06.019     Document Type: Article

References (39)

1. Croft S., and Coombs G.H. Leishmaniasis-current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 19 (2003) 502-508
2. Berman J. Clinical status of agents being developed for leishmaniasis. Exp Opin Invest Drugs 14 (2005) 1337-1346
3. Balaña-Fouce R., Cubría J.C., Reguera R.M., and Ordóñez D. The pharmacology of leishmaniasis. Gen Pharmacol 30 (1998) 435-443
4. Champoux J.J. DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 70 (2001) 369-413
5. Corbett K., and Berger J.M. Structure, molecular mechanisms, and evolutionary relationships in DNA topoisomerases. Annu Rev Biophys Biomol Struct 33 (2004) 95-118
6. Wang J. DNA topoisomerases. Annu Rev Biochem 65 (1996) 635-692
7. Redinbo M., Stewart L., Kuhn P., Champoux J.J., and Hol W.G. Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science 279 (1998) 1504-1513
8. Stewart L., Ireton G.C., and Champoux J.J. The domain organization of DNA topoisomerase I. J Biol Chem 271 (1996) 7602-7608
9. Stewart L., Ireton G.C., and Champoux J.J. A functional linker in human topoisomerase I is required for maximum sensitivity to camptothecin in a DNA relaxation assay. J Biol Chem 274 (1999) 32950-32960
10. Bodley A., Chakraborty A.K., Xie S., Burri C., and Shapiro T.A. An unusual type IB topoisomerase from African trypanosomes. Proc Natl Acad Sci USA 100 (2003) 7539-7544
11. Villa H., Otero Marcos A.R., Reguera R.M., Balaña-Fouce R., García-Estrada C., Pérez-Pertejo Y., et al. A novel active DNA topoisomerase I in Leishmania donovani. J Biol Chem 278 (2003) 3521-3526
12. Reguera R., Redondo C.M., Gutiérrez de Prado R., Pérez-Pertejo Y., and Balaña-Fouce R. DNA topoisomerase I from parasitic protozoa: a potential target for chemotherapy. Biochim Biophys Acta 1759 (2006) 117-131
13. Das B.B., Sengupta T., Ganguly A., and Majumder H.K. Topoisomerases of kinetoplastid parasites: why so fascinating?. Mol Microbiol 62 (2006) 917-927
14. Krogh B., and Shuman S. Catalytic mechanism of DNA topoisomerase IB. Mol Cell Biol 5 (2000) 1035-1041
15. Davies D., Mushtaq A., Interthal H., Champoux J.J., and Hol W.G. The structure of the transition state of the heterodimeric topoisomerase I of Leishmania donovani as a vanadate complex with nicked DNA. J Mol Biol 357 (2006) 1202-1210
16. Tamura H., Kohchi C., Yamada R., Ikeda T., Koiwai O., Patterson E., et al. Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites. Nucl Acids Res 19 (1991) 69-75
17. Knab A., Fertala J., and Bjornsti M.A. Mechanisms of camptothecin resistance in yeast DNA topoisomerase I mutants. J Biol Chem 268 (1993) 22322-22330
18. Marquis J.F., Hardy I., and Olivier M. Topoisomerase I amino acid substitutions, Gly185Arg and Asp325Glu, confer camptothecin resistance in Leishmania donovani. Antimicrob Agents Chemother 49 (2005) 1441-1446
19. Díaz-González R., Pérez-Pertejo Y., Redondo C.M., Pommier Y., Balaña-Fouce R., and Reguera R.M. Structural insights on the small subunit of DNA topoisomerase I from the unicellular parasite Leishmania donovani. Biochimie 89 (2007) 1517-1527
20. Hann C.L., Carlberg A.L., and Bjornsti M.A. Intragenic suppressors of mutant DNA topoisomerase I-induced lethality diminish enzyme binding of DNA. J Biol Chem 273 (1998) 31519-31527
21. Altschul S.F., MaddenTL, Schäffer A.A., Zhang J., Zhang Z., Miller W., et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucl Acids Res 25 (1997) 3389-3402
22. Ivens A.C., Peacock C.S., Worthey E.A., Murphy L., Aggarwal G., Berriman M., et al. The genome of the kinetoplastid parasite, Leishmania major. Science 309 (2005) 436-442
23. Ito H., Fukuda Y., Murata K., and Kimura A. Transformation of intact yeast cells treated with alkali cations. J Bacteriol 153 (1983) 163-168
24. Jazwinski S.M. Preparation of extracts from yeast. Methods Enzymol 182 (1990) 154-174
25. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72 (1976) 248-254
26. Thrash C., Voelkel K., DiNardo S., and Sternglanz R. Identification of Saccharomyces cerevisiae mutants deficient in DNA topoisomerase I activity. J Biol Chem 259 (1984) 1375-1377
27. Antony S., Kohlhagen G., Agama K., Jayaraman M., Cao S., Durrani F.A., et al. Cellular topoisomerase I inhibition and antiproliferative activity by MJ-III-65 (NSC 706744), an indenoisoquinoline topoisomerase I poison. Mol Pharmacol 67 (2005) 523-530
28. Woo M., Vance J.R., Marcos A.R., Bailly C., and Bjornsti M.A. Active site mutations in DNA topoisomerase I distinguish the cytotoxic activities of camptothecin and the indolocarbazole, rebeccamycin. J Biol Chem 277 (2002) 3813-3822
29. Wittschieben J., Petersen B.O., and Shuman S. Replacement of the active site tyrosine of vaccinia DNA topoisomerase by glutamate, cysteine or histidine converts the enzyme into a site-specific endonuclease. Nucl Acids Res 26 (1998) 490-496
30. Interthal H., Quigley P.M., Hol W.G., and Champoux J.J. The role of lysine 532 in the catalytic mechanism of human topoisomerase I. J Biol Chem 279 (2004) 2984-2992
31. Bodley A.L., and Shapiro T.A. Molecular and cytotoxic effects of camptothecin, a topoisomerase I inhibitor, on trypanosomes and Leishmania. Proc Natl Acad Sci USA 92 (1995) 3726-3730
32. Staker B., Hjerrild K., Feese M.D., Behnke C.A., Burgin Jr. A.B., and Stewart L. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc Natl Acad Sci USA 99 (2002) 15387-15392
33. Lynn R., Bjornsti M.A., Caron P.R., and Wang J.C. Peptide sequencing and site-directed mutagenesis identify tyrosine-727 as the active site tyrosine of Saccharomyces cerevisiae DNA topoisomerase I. Proc Natl Acad Sci USA 86 (1989) 3559-3563
34. Fiorani P., Chillemi G., Losasso C., Castelli S., and Desideri A. The different cleavage DNA sequence specificity explains the camptothecin resistance of the human topoisomerase I Glu418Lys mutant. Nucl Acids Res 34 (2006) 5093-5100
35. Fiorani P., Bruselles A., Falconi M., Chillemi G., Desideri A., and Benedetti P. Single mutation in the linker domain confers protein flexibility and camptothecin resistance to human topoisomerase I. J Biol Chem 278 (2003) 43268-43275
36. Kubota N., Kanzawa F., Nishio K., Takeda Y., Ohmori T., Fujiwara Y., et al. Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line. Biochem Biophys Res Commun 188 (1992) 571-577
37. Fiorani P., Amatruda J.F., Silvestri A., Butler R.H., Bjornsti M.A., and Benedetti P. Domain interactions affecting human DNA topoisomerase I catalysis and camptothecin sensitivity. Mol Pharmacol 56 (1999) 1105-1115
38. Megonigal M., Fertala J., and Bjornsti M.A. Alterations in the catalytic activity of yeast DNA topoisomerase I result in cell cycle. J Biol Chem 272 (1997) 12801-12808
39. Urasaki Y., Laco G., Takebayashi Y., Bailly C., Kohlhagen G., and Pommier Y. Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506, and its topoisomerase I binding site. Cancer Res 61 (2001) 504-508